source
- GSK’s B7-H4 ADC shows 62% response in platinum-resistant ovarian cancer, PFS 11 monthsGSK’s global head of oncology R&D presented new early-stage data on its B7-H4‑directed antibody‑drug conjugate, mo‑rez, at the ESMO conference in Madrid. The update focused on the ongoing Behold‑1…
- AMA chief urges regulators to keep pace with emerging AI-driven medical careThe American Medical Association’s chief executive highlighted the rapid progress toward autonomous, AI‑based medical treatments and warned that regulatory frameworks are lagging behind. He emphasi…